UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549
 
Form 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported): January 8, 2018
 
 
INNOVUS PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
 
Nevada
000-52991
90-0814124
(State or other jurisdiction of incorporation)
(Commission
File Number)
(IRS Employer Identification No.)
 
8845 Rehco Road, San Diego, CA
 
92122
(Address of Principal Executive Offices)
 
(Zip Code)
 
Registrant’s telephone number, including area code: (858) 964-5123
 
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 
 

 
 
 
In this report, “Innovus Pharmaceuticals,” “Innovus Pharma,” “the Company”, “we,” “us” and “our” refer to Innovus Pharmaceuticals, Inc., and/or one or more of our wholly-owned subsidiaries, unless the context otherwise provides. Innovus Pharma® is a registered service mark of Innovus Pharmaceuticals, Inc.
 
Item 8.01 – Other Events
 
On January 8, 2018, the Company issued a press release announcing that it had entered into an exclusive license and distribution agreement with Acerus Pharmaceuticals Corporation (“Acerus”), a Canadian company, for the distribution of its UriVarx® product in Canada. Pursuant to the Acerus agreement, Acerus shall provide Innovus with an up-front payment and will be eligible to receive up to CAD$1.65 million in milestone payments based on Acerus achieving certain sales targets and an agreed-upon transfer price. Acerus also has minimum annual purchase requirements for UriVarx® during the term of the agreement.
 
The full text of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.
 
Item 9.01 -- Financial Statements and Exhibits
 
(d) Exhibits
 
  Exhibit Number
 
  Description
 
  Press release issued January 8, 2018.
 
 
 
 
 
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.
 
Date: January 8, 2018
INNOVUS PHARMACEUTICALS, INC.
 
 
 
By: /s/ Randy Berholtz
Randy Berholtz
Executive Vice President, Corporate Development
 
 
 
 
 
 
EXHIBIT INDEX
 
  Exhibit Number
 
  Description
 
  Press release issued January 8, 2018.